deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT03093870

Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer (TreeTopp)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy

Sponsor: ASLAN Pharmaceuticals

Conditions Biliary Tract Cancer
Interventions Capecitabine Placebo (for Varlitinib) Varlitinib
Updated 14 times since 2017 Last updated: Jul 12, 2021 Started: Jul 4, 2017 Primary completion: Nov 12, 2019 Completion: Apr 17, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Biliary Tract Cancer and is currently completed. ASLAN Pharmaceuticals leads this study, which shows 14 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Apr 2017 – ~Nov 2017 · 7 months · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Jan 2021 · 23 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~May 2023 · 20 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. May 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  5. Sep 2021 — May 2023 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 9 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  2. Feb 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  3. Jan 2019 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  4. Nov 2018 — Jan 2019 [monthly]

    Recruiting PHASE2_PHASE3

  5. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2_PHASE3

  6. Jul 2018 — Oct 2018 [monthly]

    Recruiting PHASE2_PHASE3

  7. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2_PHASE3

  8. Nov 2017 — Jun 2018 [monthly]

    Recruiting PHASE2_PHASE3

    Status: Not Yet Recruiting → Recruiting

  9. Apr 2017 — Nov 2017 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ASLAN Pharmaceuticals
  • CMIC Co, Ltd. Japan
  • Syneos Health
  • bioRASI, LLC
Data source: ASLAN Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Budapest, Hungary , Camperdown, Australia , Charlotte, United States , Chiba, Japan , Dallas, United States , Detroit, United States , Durham, United States , Gilbert, United States , Hong Kong, Hong Kong and 11 more locations